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Abstract
Non-coding RNA GAS5 (growth arrest-specific transcript 5) is a 5′-TOP (5′-terminal oligopyrimidine tract)
RNA, whose translation, and consequently also stability, is controlled by the mTOR (mammalian target of
rapamycin) pathway. GAS5 was identified by functional expression cloning and is necessary and sufficient for
normal growth arrest in both leukaemic and untransformed human T-lymphocytes. GAS5 is also required
for the inhibitory effects of rapamycin and its analogues on T-cells. The striking functional effects of GAS5
may be mediated through the snoRNAs (small nucleolar RNAs) encoded in its introns and/or through the
unusual folding of the mRNA itself, which sequesters, and therefore inhibits, the glucocorticoid receptor.
Introduction: the identification of GAS5
(growth arrest-specific transcript 5)
The control of cell proliferation and survival is crucial
to human physiology and pathology. This is particularly
important for lymphocytes, since the regulation of these
cells at the individual level is essential, both for producing
and controlling the adaptive immune response, and for self-
tolerance which is an essential property of a healthy immune
system.
A logical consequence of the importance of these controls
in healthy individuals is that defects in these systems underlie
many disease processes, from autoimmune disease to cancer
[1,2]. The pharmaceutical manipulation of these processes,
e.g. by inhibition of the crucial protein kinase mTOR
(mammalian target of rapamycin), is critically important for
immunosuppression [3], as well as for leukaemia therapy
[4]. Although investigations into the regulation of cell
proliferation have been carried out over several decades,
comparably extensive investigations into the molecular
mechanisms controlling cell death are more recent [5,6]. These
investigations have shown that the mechanisms regulating
both processes are very complex, and that there are many
indications that critical elements are yet to be discovered
[7–10].
Although considerable progress in understanding the
mechanisms controlling cell proliferation and survival has
been made by the analysis of established regulatory
components and the molecules with which they interact,
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forward genetics [11] provides a complementary strategy with
the important advantage that it is entirely independent of
previously established knowledge. In addition, this approach
identifies genes playing causal roles in the cell death process,
and distinguishes this crucial group of genes from those
which, while being differentially expressed, do not affect
the cell death/survival decision [10]. This in-built focus
on genes that play causal roles inevitably identifies those
most likely to be of real importance, both biologically and
medically. Twenty-two candidate apoptosis regulators have
been identified in this way [12] and, in addition to GAS5
(see below), six of them have been confirmed as regulators of
lymphoid and/or myeloid apoptosis {i.e. LUCA-15/RBM5
[13–16], protein phosphatase 4 [17–19], v-ATPase E (vacuolar
ATPase E) [20], Fau [21–23], RACK1 (receptor for activated
C-kinase 1) [24] and PLAC8/Onzin [12]}.
The functional expression cloning strategy resulted in the
identification of GAS5 [12], originally isolated by Schneider
et al. [25], from a subtraction cDNA library identifying
genes enriched on growth arrest. GAS5 is encoded at 1q25,
an important locus for the development of the autoimmune
disease SLE (systemic lupus erythematosus [26–28]). GAS5
itself has been identified as an SLE-susceptibility gene in a
mouse model system [29]. Several types of leukaemia and
lymphoma display abnormalities in 1q25 [30,31]. GAS5 is
involved in a chromosomal rearrangement with Notch 1
in radiation-induced thymic lymphoma [32], and is up-
regulated 3.3-fold (the greatest up-regulation for any gene
in the whole-genome array) by oncogenic kinases associated
with myeloproliferative disorders [33].
GAS5 encodes snoRNAs (small nucleolar RNAs) in its
introns, and its exons contain a small ORF (open reading
frame) that does not encode a functional protein [34]; other
mammalian snoRNAs are also encoded in the introns of genes
coding for non-functional proteins [35]. GAS5 is a 5′-TOP
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(5′-terminal oligopyrimidine tract) RNA, i.e. it has a TOP
sequence at its 5′-end. This motif is shared by a hundred or so
different mRNAs encoding ribosomal proteins, translation
initiation factors and other proteins involved in protein
synthesis. The translation of 5′-TOP RNAs is controlled
at least in part by the mTOR pathway [36], and this may
explain the influence of the mTOR pathway on GAS5 levels
[37]. Since the GAS5 transcript contains a stop codon in
an early exon, when cells are actively growing and all 5′-
TOP RNAs are being actively translated, GAS5 transcripts
are rapidly degraded by nonsense-mediated decay. When
the translation of 5′-TOP transcripts is reduced in growth
arrested or rapamycin-treated cells, nonsense-mediated decay
no longer occurs and GAS5 transcript levels increase [37],
consistent with its original designation as a growth-arrest-
specific transcript [25].
The role of GAS5 in T-cell growth arrest
The isolation of a W7.2 mouse thymoma clone that was
resistant to a normally lethal dose of gamma radiation, and
which contained a fragment of GAS5 sequence [12], was
the first indication that modulation of GAS5 expression
levels could provide resistance to apoptosis. The GAS5
transcript gives rise to many different splice variants, and
the expression of several, but not all, of these, produced
growth arrest and some induction of apoptosis in the
leukaemic T-cell line CEM-C7 [38]. This indicated that
GAS5 may be playing an active role in growth arrest,
rather than simply being passively associated with growth
arrest. However, overexpression studies may sometimes
result in artefacts that have little physiological relevance. For
this reason, endogenous GAS5 expressed in the CEM-C7
leukaemic T-cells was down-regulated using three different
GAS5 siRNAs (small interfering RNAs). Although this
produced little discernible effect on the exponential phase
of cell growth, the growth arrest that occurred in control
cells was markedly inhibited by down-regulation of GAS5
by siRNAs (Figure 1). This indicated that endogenously
expressed GAS5 was required for normal growth arrest
in this leukaemic T-cell line. It is interesting to note that
this experiment clearly demonstrates that the growth arrest
normally occurring in T-cell cultures cannot be simply the
result of complete exhaustion of nutrients, since the GAS5
siRNA-treated cultures continue to grow above the den-
sity of control cultures. Growth arrest in control cultures,
therefore, is a signal-mediated event, and this signal, leading
to growth arrest, requires GAS5. Down-regulation of GAS5
also protected CEM-C7 T-cells from the loss of colony-
forming ability produced by 3-days serum withdrawal or
dexamethasone treatment [38].
Overexpression and down-regulation of GAS5 produced
similar effects on primary cultures of proliferating human T-
lymphocytes, that is, on untransformed human T-cells [38].
GAS5 expression is therefore necessary and sufficient for
normal growth arrest in human T-cells, suggesting that it
may be of considerable biological and clinical importance.
Figure 1 GAS5-specific siRNAs regulate the growth of CEM-C7
cells and delay growth arrest
CEM-C7 T-leukaemic cells were transfected with specific GAS5 siRNAs
or negative control siRNA [( − )siRNA] and cultured at 37◦C. Viable
cell numbers were determined by vital dye staining (means ± S.E.M.)
from six independent experiments. *P<0.01 compared with ( − )siRNA.
Reproduced from Mourtada-Maarabouni et al. [38] with permission.
The role of GAS5 in the inhibitory effects of
rapamycin on human T-cells
Since the mTOR protein kinase plays a pivotal role in the
control of cell growth and proliferation, and the GAS5
transcript is a 5′-TOP RNA whose translation is known to be
controlled, at least in part, by the mTOR pathway, the poten-
tial involvement of GAS5 in the inhibitory effects of mTOR
inhibitors, such as rapamycin, has been investigated [39].
Down-regulation of endogenous GAS5 levels by siRNAs
(as above) substantially reduced the inhibitory effects of
rapamycin and its analogues (rapalogues) on both leukaemic
and untransformed human T-cells. GAS5 siRNAs reduced
the inhibitory effects of rapamycin, as measured by BrdU
(bromodeoxyuridine) incorporation, Ki67 immunostaining,
direct counting of viable cell number and propidium iodide
staining followed by FACS analysis. Dependence on GAS5
was also demonstrated for the clinically important rapamycin
analogues temsirolimus and everolimus [39]. Figure 2 shows
the alleviation of the inhibitory effects of temsirolimus and
everolimus by three different GAS5 siRNAs, as monitored
by BrdU incorporation.
Alleviation of inhibitory effects by GAS5 siRNAs was sub-
stantial both for leukaemic and untransformed T-cells, being
approx. 50 % or more [39]. The true magnitude of the pro-
tective effect is likely to be greater than those since the
transfection efficiency for these experiments was between
65 % and 85 %, that is, 15–35 % of cells did not contain GAS5
siRNAs. Even allowing for this, the protective effect of GAS5
siRNAs is clearly incomplete, as would be expected given
the complexity of the effects of mTOR activity and mTOR
inhibition [40]. However, these observations demonstrate
that most of the inhibitory effects of rapalogues on both
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Figure 2 GAS5-specific siRNAs protect the proliferation of MOLT-4
T-leukaemic cells from the inhibitory effects of rapalogues
At 48 h after transfection, siRNA-transfected cells were incubated with
temsirolimus (5 nM) or everolimus (10 nM) for 48 h. MOLT-4 T-leukaemic
cell proliferation was assessed using the BrdU colorimetric ELISA
assay. Results are percentage inhibition of cell proliferation compared
with controls in the absence of inhibitor. Means ± S.E.M. from five
independent experiments. *P<0.01 compared with ( − )siRNA. Similar
effects were observed with the two leukaemic T-cell lines, CEM-C7
and MOLT4, and with untransformed human peripheral blood T-cells.
Reproduced from [39]: Mourtada-Maarabouni, M., Hasan, A.M., Farzaneh,
F. and Williams, G.T. (2010) Inhibition of human T-cell proliferation by
mammalian target of rapamycin (mTOR) antagonists requires noncoding
RNA growth-arrest-specific transcript 5 (GAS5) Mol. Pharmacol. 78,
19–28.
untransformed and transformed human T-cells are mediated
through GAS5.
Down-regulation of GAS5 produced a much smaller
protective effect against the ATP-site mTOR inhibitor Torin
1 (M. Mourtada-Maarabouni and G.T. Williams, unpublished
work). Since Torin 1 [41] and the other ATP-site inhibitors
of mTOR antagonize a broader range of the effects of
mTOR than rapamycin and its analogues, this observation
is consistent with the requirement for GAS5 in signalling
pathways specifically affected by the rapalogues. Inhibitory
effects produced by the ATP-site mTOR inhibitors such as
Torin 1 are very likely to include effects on pathways which
do not require GAS5, so that the inhibitory effects of these
compounds are much less affected by GAS5 siRNAs.
Molecular mechanisms which may account
for the striking functional effects of GAS5
Since the largest ORF in GAS5 mRNA is small, poorly
conserved, and unlikely to encode a functional protein, it
has naturally been assumed that the important functional
elements of the GAS5 gene are the snoRNAs encoded in
its introns. The human GAS5 gene encodes 10 box C/D
snoRNAs, which are predicted to act as guide RNAs for
the methylation of specific residues in ribosomal RNA. This
methylation is important for fine tuning rRNA function and
has been thought of as essentially a housekeeping activity.
However, U50, a separately encoded box C/D snoRNA, has
recently been implicated in the development of both prostate
cancer [42] and breast cancer [43]. snoRNA U50 has therefore
been suggested to be a potential tumour suppressor gene, as
a 2 bp deletion in U50 is associated with clinically significant
prostate cancer [42]. In addition, overexpression of wild-type
U50 in a prostate cancer cell line significantly reduced colony-
forming efficiency [42]. These observations suggest that box
C/D snoRNAs may play previously unsuspected roles in
controlling cell fate.
A further very interesting and unexpected twist in the
GAS5 story has recently been provided by Kino et al.
[44]. This group showed that, although the mature spliced
form of the GAS5 mRNA does not encode a functional
protein, it nevertheless has important functional activity.
This activity appears to derive from folding of the mRNA
itself to form a mimic of the DNA-binding domain that
normally interacts with the glucocorticoid receptor. GAS5
mRNA itself thus sequesters the glucocorticoid receptor and
inhibits the glucocorticoid pathway. It is therefore through
this very novel mechanism that GAS5 may produce some of
its important functional effects. However, this cannot be the
whole story, since it is difficult to account for the inhibition of
dexamethasone-induced T-cell death by GAS5 siRNAs [38]
by such a mechanism.
Evolution of GAS5
GAS5 appears to provide an important link, at least in
T-cells, between the control of protein synthesis, and
therefore cell growth, by the mTOR pathway, and the control
of proliferation and cell survival. It is attractive to speculate
that at some time in its evolutionary history the GAS5
gene, in common with most other 5′-TOP RNAs, encoded
a functional protein, perhaps a ribosomal protein. Once the
ORF encoding this protein became redundant through gene
duplication, the appearance of an early stop codon through
point mutation would not have had a deleterious effect on the
cell. In addition, since the GAS5 transcript is protected from
nonsense-mediated decay and accumulates on inhibition of
translation, the acquisition of anti-proliferative and anti-
survival signals by the GAS5 gene would immediately link
inhibition of translation to inhibition of the cell cycle. The
anti-proliferative and anti-survival signals provided by GAS5
may be mediated through an as yet poorly defined activity
of the encoding snoRNAs, through the inhibition of steroid
receptor pathways by the GAS5 mRNA itself, or through
some combination of these effects (and possibly others too!).
Clinical relevance of the studies on GAS5
The unexpected observation that T-cell growth arrest and
the inhibitory effects of rapamycin and its analogues are
dependent on non-coding RNA GAS5 may have important
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clinical implications, because of the use of these compounds in
immunosuppression and in cancer therapy. Down-regulation
of GAS5 produces a much greater effect on the inhibition
by rapalogues than on inhibition by the broader specificity
inhibitor Torin 1. Further investigation and subsequent
targeting of the GAS5 pathway may therefore allow
greater specificity in immunosuppression and cancer therapy,
eliminating or reducing unwanted side effects in both cases.
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